NCT01489033CompletedPhase 1
Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.
Roxall Medicina España S.A2 sites in 1 country42 target enrollmentStarted: January 2010Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Roxall Medicina España S.A
- Enrollment
- 42
- Locations
- 2
- Primary Endpoint
- Number and seriousness of both local and systemic adverse reactions
Study Overview
Brief Summary
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic disease the aim of this study was to assess safety and tolerability of three different subcutaneous immunotherapy dose escalations in patients allergic to the pollen of Phleum pratense.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must sign the informed consent form.
- •Patients must be between 18 and 60 years of age.
- •Patients who obtained a prick test result greater or equal to 3 mm diameter and a specific IgE greater or equal to class 2 (CAP/PHADIA) to Phleum pratense.
- •Patients with seasonal allergic rhinoconjunctivitis against Phleum pratense during a minimum of 2 years prior to study participation. Although allergic rhinoconjunctivitis is the pathology under study, the inclusion of patients with mild or moderate concomitant asthma is allowed.
- •Patients will preferably be monosensitized to Phleum pratense. Polysensitized patients to other seasonal allergens will be accepted if sensitizations are caused by Pollens whose seasons do not overlap with Phleum pratense.
- •Polysensitized patients to perennial allergens will also be accepted if not clinically relevant during the study period.
- •Women of childbearing potential must have a negative urine pregnancy test at Screening visit/Visit 0
- •Women of childbearing potential must agree to use an appropriate contraception method during the study if they are sexually active.
Exclusion Criteria
- •Stable and continued use of medication for allergic pathology during 2 weeks prior to inclusion.
- •Patients sensitised to other overlapping seasonal allergens and with specific IgE levels greater or equal to class 2 CAP/PHADIA.
- •Patients who received immunotherapy in the previous 5 years for Phleum pratense or for any allergen with cross reactivity or patients that are currently receiving immunotherapy for any allergen.
- •Patients with severe asthma or FEV1 lower than 60% or asthma requiring inhaled or systemic corticoid treatment at the time of study entry or within 8 weeks prior to treatment commencement.
- •Patients with: immunological, cardiac, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study.
- •Patients with a previous history of anaphylaxis
- •Patients with unstable angina
- •Patients with uncontrolled hypertension
- •Patients with clinically significant arrythmias
- •Patients with neoplasia
- •Patients with clinically relevant malformations of the upper respiratory tract.
- •Other chronic or immunological disease that could interfere with the assessment of the investigation product or that could generate any additional risk for the patient
- •Patients who have participated in another clinical trial within 3 month prior to enrolment.
- •Patients under treatment with tricyclic antidepressives, psychotropics or beta-blockers
- •Female patients who are pregnant or breast-feeding or women of childbearing potential that do not agree to use an appropriate contraception method during the study if they are sexually active, if they have not been surgical sterilised or present any other incapacity to bear
- •Patient who does not attend the visits
- •Patient's lack of collaboration or refusal to participate.
Outcomes
Primary Outcomes
Number and seriousness of both local and systemic adverse reactions
Time Frame: From informed consent signature (V0) until the end of patient participation in the study (depending on the treatment assigned between 4 and 8 weeks )
Secondary Outcomes
- Immunoglobulin levels (IgE specific, IgG total and IgG4) and prick test dose response(Before (V0) and after treatment (depending on the treatment assigned between 4 and 8 weeks))
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)Allergic RhinoconjunctivitisNCT01489020Roxall Medicina España S.A48
Completed
Phase 2
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum PratenseAllergic RhinoconjunctivitisNCT01567306Roxall Medicina España S.A151
Unknown
Not Applicable
Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLCNSCLC and TheropyNCT04530097Shanghai 10th People's Hospital260
Terminated
Phase 1
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisSclerosis, MultipleAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesNCT03540485Fundación Pública Andaluza para la gestión de la Investigación en Sevilla25
Completed
Phase 2
Dental Pain 3rd Molar Tooth Extraction GW842166PainNCT00444769GlaxoSmithKline112